Tag: IL-6

Colchicine

Cochicine does not improve mortality in COVID19. St Emlyn’s

This week the RECOVERY trial has released the first results from the Colchicine arm of the trial. We await the pre-print and the peer reviewed paper, but we are already very familiar with the trial

tocilizumab

Tocilizumabulous? A special offer on IL-6 with Tocilizumab.

It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it. Maybe not the one intervention

tocilizumab

JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s

In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a significant benefit. This short blog

Tocilizumab

Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s

Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic agent for patients with severe

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

azithromycin stemlyns covid-19

JC: Azithromycin in patients hospitalised with COVID-19

As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were first hearing about a respiratory

The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s

A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have been shown to strongly correlate

Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s

A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring systems over many years (for

Tocilizumaybe? Immune modulation in COVID-19 @StEmlyns

I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is COVID19. This follows a press

Translate »